Lupin bags tentative USFDA approval for DETAF Tablets

31 Jan 2023 , 12:50 PM

Lupin Limited, a leading global pharmaceutical company, has been granted provisional approval from the US Food and Drug Administration (FDA) as part of the US President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide (DETAF) Tablets.

This product will be produced at Lupin’s manufacturing site located in Nagpur, India.

Naresh Gupta, President of API and Global Institution Business at Lupin, expressed his company’s dedication to offering cost-effective and high-quality healthcare solutions to patients in low- and middle-income nations. He expressed his satisfaction with the tentative approval of DETAF by the USFDA, which will significantly boost Lupin’s offerings for treating HIV.

The availability of DETAF, a promising new medication for the treatment of HIV infections, will bring a much-needed boost to low and middle-income nations worldwide.

At around 12.35 PM, Lupin was trading at Rs736.70, up by 0.27% against the previous close of Rs734.70 on NSE. The counter touched an intraday high and low of Rs738.45 and Rs727.30 respectively.

For feedback and suggestions, write to us at [e-mail]